For recipient characteristics, the recipient age, race, ABO blood type, underlying liver disease, height, weight, cold ischemia time, body mass index (BMI), laboratory model for end-stage liver disease (MELD) score, albumin, bilirubin, international normalized ratio (INR), creatinine and immunosuppression maintenance with tacrolimus, cyclosporin, mycophenolate mofetil and steroids at discharge were all statistically different among the four groups. This evidence concerns the gene ALB and liver disorder.